Sjögren's syndrome: Old and new therapeutic targets

贝里穆马布 美罗华 免疫学 阿巴塔克普 阿纳基纳 B细胞激活因子 托珠单抗 医学 疾病 B细胞 内科学 类风湿性关节炎 淋巴瘤 抗体
作者
Clio P. Mavragani,Haralampos Μ. Moutsopoulos
出处
期刊:Journal of Autoimmunity [Elsevier BV]
卷期号:110: 102364-102364 被引量:140
标识
DOI:10.1016/j.jaut.2019.102364
摘要

Sjögren's syndrome (SS) is a prototype autoimmune disease characterized by oral and ocular mucosal dryness following chronic inflammation of salivary and lachrymal glands, respectively. Profound B cell hyperactivity along with systemic manifestations including fatigue, musculoskeletal complaints, features related to hepatic, pulmonary, renal and nervous system involvement, as well as lymphoma development can be also present. Despite that activation of both innate and adaptive immune pathways has been long well documented in SS pathogenesis, systemic immunosuppression in SS, in contrast to other autoimmune diseases, has been largely inefficacious. Biological agents previously implemented in successful therapeutic outcomes in rheumatoid arthritis (RA), such as anti-TNF agents, anakinra, tocilizumab and rituximab failed to reach primary outcomes in randomized double-blind controlled trials in the context of SS. Abatacept and belimumab, already licensed for the treatment of RA and lupus respectively, as well combination regimens of both rituximab and belimumab hold some promise in alleviation of SS-specific complaints, but data from large controlled trials are awaited. Recent advances in dissecting the molecular pathways underlying SS pathogenesis led to an expanding number of novel biological compounds directed towards type I interferon system, antigen presentation, costimulatory pathways, B and T cell activation, as well as germinal center formation. While targeting of cathepsin-S (Petesicatib), inducible costimulator of T cells ligand (prezalumab), and lymphotoxin beta receptor (baminercept) failed to fulfil the primary outcome measures, preliminary results from two randomized placebo controlled trials on CD40 blockade (Iscalimab) and B-cell activating factor receptor (Ianalumab) inhibition resulted in significant reduction of SS disease activity, with a favorable so far safety profile. Results from administration of other kinase inhibitors, a transmembrane activator and calcium-modulator and cytophilin ligand interactor TACI fusion protein (RC18), as well as low dose recombinant interleukin-2 to expand T-regulatory cells are currently awaited.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
所所的应助被阳光花丝采纳,获得10
刚刚
1秒前
虚幻的靖儿完成签到 ,获得积分10
1秒前
猴王完成签到,获得积分10
3秒前
天天向上的应助被友好天蓝采纳,获得10
4秒前
sai完成签到,获得积分20
5秒前
秦白发布了新的文献求助10
5秒前
yh完成签到,获得积分10
5秒前
5秒前
852的应助被Minta采纳,获得10
5秒前
bkagyin的应助被lll采纳,获得10
6秒前
hhhlllmmm完成签到 ,获得积分10
7秒前
小new吗完成签到,获得积分10
7秒前
fengfengfeng完成签到,获得积分20
7秒前
zz完成签到,获得积分10
7秒前
8秒前
AstrLees完成签到 ,获得积分10
9秒前
传奇3的应助被yh采纳,获得30
9秒前
WYZ完成签到,获得积分10
10秒前
zzz发布了新的文献求助10
10秒前
刘营营完成签到,获得积分10
11秒前
11秒前
爆米花的应助被aoao采纳,获得10
11秒前
11秒前
penghuiye完成签到,获得积分10
12秒前
壮观以松完成签到,获得积分10
12秒前
13秒前
Michael完成签到,获得积分10
13秒前
14秒前
pigeon发布了新的文献求助10
15秒前
林深沉完成签到,获得积分10
16秒前
16秒前
16秒前
霜沐发布了新的文献求助10
17秒前
zhen完成签到,获得积分10
17秒前
真不爱学习完成签到 ,获得积分10
17秒前
jackhlj完成签到,获得积分10
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190478
求助须知:如何正确求助?哪些是违规求助? 9577686
关于积分的说明 21853808
捐赠科研通 7789496
什么是DOI,文献DOI怎么找? 3436407
关于科研通互助平台的介绍 2560235
邀请新用户注册赠送积分活动 2483054